Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interferon alfa + all-trans retinoic acid
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous, Intramuscular
01
Overview
This is a combination therapy consisting of interferon alfa and all-trans retinoic acid (ATRA). The combination has been studied for various hematologic disorders including multiple myeloma, chronic myeloid leukemia, and acute promyelocytic leukemia. Interferon alfa is an immunomodulator that works by enhancing the body's immune response against viral infections and certain cancers. ATRA is a vitamin A derivative that promotes cell differentiation and has shown particular efficacy in acute promyelocytic leukemia. When used in combination, these agents may work synergistically to inhibit cancer cell growth and promote differentiation of malignant cells.
- Other names
- interferon alpha + trans-retinoic acidinterferon alpha + ATRAinterferon alfa + ATRAIFN-α + ATRAIFN-alpha + ATRA
02
Targets
RARA (Retinoic acid receptor alpha)IFNAR (Immune system modulation via type I interferon receptor)RARG (Retinoic acid receptor gamma)RARB (Retinoic acid receptor beta)
Beyond the preview
Go deeper on interferon alfa + all-trans retinoic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interferon alfa + all-trans retinoic acid.